Department of Medical Oncology, The Royal Marsden Hospital NHS Foundation Trust, London, UK.
Expert Rev Anticancer Ther. 2020 May;20(5):343-354. doi: 10.1080/14737140.2020.1756780. Epub 2020 May 7.
: The incidence of advanced renal cell carcinoma (RCC) is increasing. Over the last 10 years targeted therapies have led to improved efficacy outcomes for renal carcinoma, including longer survival. However, the majority of patients develop disease progression within a year of initiation of first-line therapy. Recently a number of new regimens have been investigated including the combination of immune checkpoint inhibitors with VEGF inhibitors.: In this review, we assess the efficacy and safety of avelumab/axitinib in treatment-naïve patients with metastatic RCC and compare this combination to other current and emerging treatment regimens. In the Javelin 101 phase III registration trial, avelumab/axitinib demonstrated superior response rates and progression-free survival compared to sunitinib. However, after follow-up of 11.6 months, there was no significant difference in overall survival (OS). Avelumab/axitinib showed a tolerable safety profile. Adverse events were manageable and were in line with expected toxicities from the single agents.: Avelumab/axitinib has shown impressive efficacy and a tolerable safety profile in metastatic RCC. The future role of this treatment combination in the rapidly evolving landscape of novel combinations in this disease will have to be defined.
晚期肾细胞癌（RCC）的发病率正在上升。在过去的 10 年中，靶向治疗已使肾癌的疗效得到改善，包括生存时间延长。然而，大多数患者在一线治疗开始后一年内会出现疾病进展。最近，已经研究了许多新的方案，包括免疫检查点抑制剂与 VEGF 抑制剂联合使用。
在这篇综述中，我们评估了avelumab/axitinib 在未经治疗的转移性 RCC 患者中的疗效和安全性，并将该联合治疗方案与其他当前和新兴的治疗方案进行了比较。在 Javelin 101 期 III 期注册试验中，avelumab/axitinib 与舒尼替尼相比，显示出更高的缓解率和无进展生存期。然而，在 11.6 个月的随访后，总生存期（OS）没有显著差异。avelumab/axitinib 表现出可耐受的安全性特征。不良事件可管理，与单药治疗的预期毒性一致。
avelumab/axitinib 在转移性 RCC 中显示出令人印象深刻的疗效和可耐受的安全性特征。这种治疗联合方案在该疾病中新型联合治疗方案快速发展的背景下的未来作用将有待确定。
